We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.07%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$191M
Cap. Flow
+$102M
Cap. Flow %
8.28%
Top 10 Hldgs %
30.7%
Holding
101
New
8
Increased
39
Reduced
39
Closed
6

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$18.2M
2
EXAS
Exact Sciences
EXAS
+$18.1M
3
MDT icon
Medtronic
MDT
+$13.5M
4
NVO
Novo Nordisk
NVO
+$13.3M
5
APLS
Apellis Pharmaceuticals
APLS
+$11.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$18.9M
2
UNH icon
UnitedHealth
UNH
+$18.4M
3
CI icon
Cigna
CI
+$11.2M
4
OSCR icon
Oscar Health
OSCR
+$9.64M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
76
DELISTED
Esperion Therapeutics
ESPR
$3.26M 0.26%
1,975,000
– –
RLAY icon
77
Relay Therapeutics
RLAY
$4.41B
$3.26M 0.26%
460,000
+230,000
+100% +$1.72M
KURA icon
78
Kura Oncology
KURA
$883M
$3.25M 0.26%
166,526
– –
MDGL icon
79
Madrigal Pharmaceuticals
MDGL
$12B
$3.25M 0.26%
15,300
-11,200
-42% -$2.87M
ARVN icon
80
Arvinas
ARVN
$596M
$3.21M 0.26%
130,500
-99,500
-43% -$2.6M
KRYS icon
81
Krystal Biotech
KRYS
$9.92B
$3.09M 0.25%
17,000
-2,000
-11% -$386K
IGMS
82
DELISTED
IGM Biosciences
IGMS
$3.07M 0.25%
185,459
-9,541
-5% -$105K
BRKR icon
83
Bruker
BRKR
$8.59B
$3.06M 0.25%
44,315
+38,315
+639% +$2.48M
ACLX
84
DELISTED
Arcellx
ACLX
$2.67M 0.22%
+32,000
New +$2.13M
MEDP icon
85
Medpace
MEDP
$16.9B
$2.5M 0.2%
7,500
+5,000
+200% +$1.9M
UHS icon
86
Universal Health Services
UHS
$10.2B
$1.83M 0.15%
+8,000
New +$1.72M
IMCR icon
87
Immunocore
IMCR
$1.73B
$1.81M 0.15%
58,278
– –
PRVA icon
88
Privia Health
PRVA
$2.88B
$1.73M 0.14%
95,189
-18,811
-17% -$359K
TECH icon
89
Bio-Techne
TECH
$11.3B
$1.6M 0.13%
20,000
– –
RGEN icon
90
Repligen
RGEN
$9.28B
$1.49M 0.12%
10,000
– –
XENE icon
91
Xenon Pharmaceuticals
XENE
$6.22B
$1.38M 0.11%
35,000
– –
PLRX icon
92
Pliant Therapeutics
PLRX
$65.6M
$1.35M 0.11%
120,250
– –
AVTR icon
93
Avantor
AVTR
$9.27B
$1.14M 0.09%
44,000
-16,000
-27% -$393K
AMGN icon
94
Amgen
AMGN
$227B
$967K 0.08%
3,000
-1,250
-29% -$409K
INMB icon
95
INmune Bio
INMB
$56.6M
$961K 0.08%
178,284
– –
EW icon
96
Edwards Lifesciences
EW
$53.8B
– –
-97,500
Closed -$9.01M
PEN icon
97
Penumbra
PEN
$12.8B
– –
-23,000
Closed -$4.14M
STAA icon
98
STAAR Surgical
STAA
$1.26B
– –
-65,000
Closed -$3.09M
NARI
99
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-20,000
Closed -$963K
RVNC
100
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-701,707
Closed -$1.8M
1 2 3
4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rhenman & Partners Asset Management held 101 positions worth $1.23B, up 18% from $1.04B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $102M of net new capital in Q3 2024, opening 8 new positions and adding to 39 existing holdings. Its largest new stake was Novo Nordisk: 100,000 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Elevance Health, an estimated $18.9M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2024 buy was Novo Nordisk: 100,000 shares worth $11.9M.
  • Rhenman & Partners Asset Management added most to Inspire Medical Systems in Q3 2024, an estimated $18.2M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2024 reduction was Elevance Health, cutting an estimated $18.9M.
  • Rhenman & Partners Asset Management fully exited Edwards Lifesciences in Q3 2024, selling an estimated $9.01M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.23B portfolio in Q3 2024.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 6 in Q3 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.